RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Money4, From my notes, the original AD PET scan trial design was a double blind, randomized, 3 period crossover design for 12 AD patients and a number of age matched normal controls (the updated goal is for 16 AD patients). The trial would compare 2 dose levels of CX-717 vrs placebo. A single dose of CX-717 would be used. If companies take an early peek at results, there is usually some statistical penalty involved, but that might not matter that much to a BP in this case since it's just a small proof of concept type trial.

I think the 2nd RD trial is for a different RD related indication. Stoll hasn't given us much info on the trial designs yet, but I think the first will involve fentanyl/opioid induced RD.

Concerning CX-701, the trial is only for Phase 1, so they'll decide on an eventual clinical indication/target later.

Concerning partnering, it sounded like the only current interest has been on the extreme low-ball side of the spectrum, and Stoll said he wasn't interested in those type offers at this time.

Concerning finances, Stoll estimated approx $14 mil burn for 2008, though I think it might turn out somewhat higher. In the next 12 months they're going pretty much flat out in order to to show enough clinical progress for a partnership or M+A (buyout/merger). For 2008 they have planned 2 AD scanning trials, 2 RD trials, a Phase 1 with CX-701, moving 2 new low impacts into tox studies (CX1739, CX1763), plus moving the lead high impact into tox studies. That's a pretty full plate, but I think they realize it's now do or die.